Organon & Co.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page No. | ||
|---|---|---|
| PART I | FINANCIAL INFORMATION | 3 |
| Item 1. | Financial Statements (unaudited) | 3 |
| Condensed Consolidated Statements of Income | 3 | |
| Condensed Consolidated Statements of Comprehensive Income | 4 | |
| Condensed Consolidated Balance Sheets | 5 | |
| Condensed Consolidated Statements of Stockholders’ Equity | 6 | |
| Condensed Consolidated Statements of Cash Flows | 7 | |
| Notes to Condensed Consolidated Financial Statements (unaudited) | 8 | |
| 1.Background and Nature of Operations | 8 | |
| 2.Basis of Presentation | 8 | |
| 3.Acquisitions and Licensing Arrangements | 9 | |
| 4.Earnings per Share | 10 | |
| 5.Product and Geographic Information | 11 | |
| 6.Stock Based Compensation Plans | 12 | |
| 7.Restructuring | 13 | |
| 8.Taxes on Income | 14 | |
| 9.Inventories | 14 | |
| 10.Long-Term Debt and Short-Term Borrowings | 15 | |
| 11.Financial Instruments | 16 | |
| 12.Accumulated Other Comprehensive Income (Loss) | 18 | |
| 13.Samsung Collaboration | 19 | |
| 14.Third-Party Arrangements | 19 | |
| 15.Contingencies | 20 | |
| 16.Subsequent Events | 22 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 23 |
| Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 32 |
| Item 4. | Controls and Procedures | 32 |
| PART II | OTHER INFORMATION | 34 |
| Item 1. | Legal Proceedings | 35 |
| Item 1A. | Risk Factors | 35 |
| Item 5. | Other Information | 37 |
| Item 6. | Exhibits | 38 |
| Signatures | ||
The following notations in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (this “Form 10-Q”) have the meanings as set forth below:
“1”Indicates, in this Form 10-Q, brand names of products, that are not available in the United States.
“2”Indicates, in this Form 10-Q, brand names of products that are trademarks not owned by Organon & Co. or its subsidiaries. Humirais a trademark registered in the United States in the name of AbbVie Biotechnology Ltd.; Enbrelis a trademark registered in the United States in the name of Immunex Corporation; Remicade is a trademark registered in the United States in the name of Janssen Biotech, Inc.; Herceptin is a trademark registered in the United States in the name of Genentech, Inc.; Emgality is a trademark registered in the United States in the name of Eli Lilly and Company (used under license); Prolia and Xgeva are trademarks registered in the U.S. in the name of Amgen Inc. Brand names of products that are in all italicized letters, without the footnote, are trademarks of, or are otherwise licensed by, Organon & Co. and/or one of its subsidiaries.
-2-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.